Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology

Peptide Comparison

Thymagen vs Prostamax

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Thymagen and Prostamax share the khavinson class and carry roughly equivalent evidence (Russian Research / Russian Research). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Thymagen

Russian Research

Prostamax

Russian Research

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

Thymagen Prostamax
Class Khavinson short peptide bioregulator Khavinson peptide bioregulator
Drug class Immune Other & Emerging
Mechanism Thymic gene expression modulation Tissue-specific gene expression in prostate
Route Oral / Intranasal Oral
Half-life Short (minutes) Short (minutes)
Dosage (research) Oral capsule 1-2x daily Oral capsule 1-2x daily
Evidence tier Russian Research Russian Research
Research depth 1 indexed (PubMed 1 · CT 0 · EPMC 0) 6 indexed (PubMed 5 · CT 0 · EPMC 1)
Availability Research Research
Reported risks Limited Western evidence Limited Western data

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Thymagen or Prostamax?

Thymagen and Prostamax share the khavinson class and carry roughly equivalent evidence (Russian Research / Russian Research). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.

What is the difference between Thymagen and Prostamax?

Thymagen is classed as Khavinson short peptide bioregulator; Prostamax is classed as Khavinson peptide bioregulator. Reported mechanism: Thymagen, Thymic gene expression modulation; Prostamax, Tissue-specific gene expression in prostate. Reported half-life: Thymagen, Short (minutes); Prostamax, Short (minutes). Routes in published studies: Thymagen, Oral / Intranasal; Prostamax, Oral.

Which has stronger evidence, Thymagen or Prostamax?

Thymagen and Prostamax sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Thymagen is graded Russian Research, with 2 cited sources on its reference page and 1 indexed studies. Prostamax is graded Russian Research, with 2 cited sources on its reference page and 6 indexed studies.

Which is more accessible, Thymagen or Prostamax?

Neither Thymagen nor Prostamax is an FDA-approved drug. Catalog status: Thymagen, Research; Prostamax, Research.

Are Thymagen and Prostamax ever combined?

Thymagen and Prostamax appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…